β-glucosidase 2 Activators
β-glucosidase 2 activators mainly function through modulation of intracellular signaling pathways that affect the substrate availability or the cellular reliance on this enzyme for glycan processing. Chemicals such as Forskolin and IBMX, by elevating cAMP levels, augment substrate availability, thereby indirectly enhancing the activity of β-glucosidase 2. Similarly, Genistein, as a tyrosine kinase inhibitor, may affect substrate availability by inhibiting the cellular mechanisms that would otherwise process these substrates.
Moreover, chemicals like DAPT and PD98059 that inhibit γ-secretase and MEK, respectively, influence Notch and MAPK signaling pathways. These alterations can also indirectly affect the cellular need for β-glucosidase 2 in glycan processing. PKA and CaMKII inhibitors such as H89 and KN-93, respectively, modulate cAMP and calcium signaling pathways, thereby impacting the lysosomal and endosomal requirement for β-glucosidase 2. In summary, the modulation of these signaling pathways by various chemical inhibitors increases the cellular requirement for β-glucosidase 2, thus acting as indirect activators of the enzyme.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Elevates intracellular cAMP levels, enhancing substrate availability for β-glucosidase 2 in glycan processing. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Phosphodiesterase inhibitor that augments cAMP levels, thus increasing substrate for β-glucosidase 2. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
γ-secretase inhibitor that affects Notch signaling, thereby potentially increasing the cellular reliance on β-glucosidase 2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that disrupts the MAPK pathway. Increased substrate availability for β-glucosidase 2 in glycan processing. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
CaMKII inhibitor that affects calcium signaling and indirectly increases β-glucosidase 2 requirement in lysosomes. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
RAF1 kinase inhibitor; alters MAPK pathway, thereby altering substrate availability for β-glucosidase 2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, which alters substrate availability and thus elevates the requirement for β-glucosidase 2. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
PKCβ inhibitor; its action increases the cellular need for β-glucosidase 2 for glycan degradation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that affects AP-1 transcriptional activity, thus altering the requirement for β-glucosidase 2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor that can impact the need for β-glucosidase 2 in glycan processing pathways. | ||||||